Nuwellis
NUWENuwellis, Inc. is a medical device company delivering innovative fluid-balance technologies to improve outcomes for patients with acute and chronic cardiorenal conditions. The company's clinically validated Aquadex system offers a safe, flexible, and efficient method for removing excess fluid, backed by over 20 years of clinical data and more than 65 studies. Nuwellis targets a significant market opportunity in heart failure, critical care, and pediatric nephrology, aiming to establish a new standard in fluid management.
NUWE · Stock Price
Historical price data
AI Company Overview
Nuwellis, Inc. is a medical device company delivering innovative fluid-balance technologies to improve outcomes for patients with acute and chronic cardiorenal conditions. The company's clinically validated Aquadex system offers a safe, flexible, and efficient method for removing excess fluid, backed by over 20 years of clinical data and more than 65 studies. Nuwellis targets a significant market opportunity in heart failure, critical care, and pediatric nephrology, aiming to establish a new standard in fluid management.
Technology Platform
The Aquadex SmartFlow® System is an extracorporeal ultrafiltration platform designed for the precise, predictable, and gentle removal of excess isotonic fluid from patients with fluid overload, particularly those unresponsive to diuretic therapy.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Stepped pharmacologic care | Heart Failure | Phase 3 | |
| IV diuretic | Congestive Heart Failure | Pre-clinical | |
| IV Loop Diuretics | Heart Failure (for Example, Fluid Overload) | Pre-clinical | |
| IV Loop Diuretics (LD) | Heart Failure | Pre-clinical |
Opportunities
Risk Factors
Competitive Landscape
Nuwellis primarily competes against standard intravenous diuretics and other ultrafiltration/continuous renal replacement therapy (CRRT) devices from larger players like Baxter and Fresenius. Its differentiation lies in its dedicated focus on ultrafiltration for fluid overload, extensive cardiorenal clinical evidence, and a system positioned as more cost-effective and workflow-friendly than full CRRT machines.